About

AINIGMA Technologies brings together a team of biomedical engineers, medical doctors and business consultants with a long track record in the development of Artificial Intelligence (AI) solutions, mainly, but not exclusively, for Healthcare applications. The team of AINIGMA has been involved in both research and commercial projects with different roles, which have given us valuable experience in the development of AI algorithms, alongside with expert consulting, cognitive knowledge and efficient project management of large-scale European and national projects. The diverse background of the team members allows us to identify and address real-life problems from multiple perspectives and promote the exploitable results effectively in the right market direction. The vision of the team is to make the job of Healthcare stakeholders easier and more efficient. The realization of this vision arises from the introduction of a set of AI solutions, by exploiting Big Data analytics and Machine Learning techniques to enable the provision of high-quality products and services.

Solution & Product

1) Service: Our expert team specializes in harmonizing and mapping diverse health data from multiple sources and formats to the powerful OMOP Common Data Model (CDM). With our cutting-edge solutions, you can seamlessly integrate and standardize your data, paving the way for improved patient outcomes and groundbreaking research. OMOP, the Observational Medical Outcomes Partnership Common Data Model, revolutionizes the analysis of diverse observational databases. This innovative framework simplifies the process by transforming data from disparate sources into a standardized format and representation. With OMOP, the complex task of analyzing heterogeneous observational databases becomes streamlined and efficient. This harmonization process ensures consistency and compatibility, making it easier to draw meaningful insights from the data. 2) AI Toolset: AINIGMA Technologies is building a pipeline of tools for AI-assisted diagnosis in Ultrasound images. Indicatively, AINIGMA has created an automated deep learning workflow to classify, segment, and annotate two-dimensional (2D) videos and Doppler modalities in echocardiograms. This workflow aims to replace the time-consuming and error-prone manual interpretation of echocardiograms, which is currently used to assess cardiac systolic and diastolic function for heart failure diagnosis and management. The further development includes a market-available Graphical User Interface.

Innovation & Scalability

1)For the harmonization service: This novel method simplifies the interoperability of various health information systems by standardizing and integrating heterogeneous medical data sources. Harmonizing medical data enables seamless communication between healthcare providers while also improving patient care overall. In addition it encourages cooperative research activities and enables more individualized and data-driven approaches to medical treatment. Its capacity to handle enormous and diverse datasets from many sources, including wearables and electronic health records, accounts for its scalability. and makes it an essential element in the global progress of healthcare systems, particularly as the need for comprehensive and integrated healthcare solutions continues to rise. 2)For the AI toolset: Using a Graphical User Interface (GUI) to enable AI-assisted ultrasound diagnosis is a ground-breaking innovation. In addition to streamlining the diagnostic procedure, this user-friendly interface uses artificial intelligence to improve sensitivity and specificity. Healthcare practitioners can seamlessly engage with the AI algorithms by using the GUI, which offers a visually intuitive platform for ultrasound picture interpretation. This solution's scalability is also impressive because it can easily interact with a variety of ultrasound devices and adjust to changing medical data. Given the growing need for reliable and effective diagnostic tools, a broad application is foreseen.

Traction & achievements

AINIGMA has establishments in Belgium and Greece. The parent company was founded in November 2020 in Belgium, while our branch in Greece initiated in January 2023. Within the approximately three years of the company's activity, we have achieved significant results in sourcing funds for research and innovation, participating in 12 European projects under the HORIZON Europe framework to date (10 ongoing and 2 pending to start). We are now at a stage where the research process is 'transforming' into products that can take a position in the European and/or Global market.

Team & Why Us

Our continuously growing team emphasizes in an interdisciplinary approach, by bringing together biomedical engineering, medicine, business development and public health. We bring together experienced and enthusiastic researchers and professionals with a long track record on the previously mentioned fields. This fact makes the AINIGMA team ideal for the end-to-end development of innovative healthcare solutions with explosive market potential.

Funding Needs

Our current short- and mid-term goal is to "shift gears" from research and development to the transformation of our solutions and services to market-available products. We are looking for Series A funding opportunities.